These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 16364920)

  • 1. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.
    Garnett MJ; Rana S; Paterson H; Barford D; Marais R
    Mol Cell; 2005 Dec; 20(6):963-9. PubMed ID: 16364920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAF protein-serine/threonine kinases: structure and regulation.
    Roskoski R
    Biochem Biophys Res Commun; 2010 Aug; 399(3):313-7. PubMed ID: 20674547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation and role of Raf-1/B-Raf heterodimerization.
    Rushworth LK; Hindley AD; O'Neill E; Kolch W
    Mol Cell Biol; 2006 Mar; 26(6):2262-72. PubMed ID: 16508002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-Raf and C-Raf signaling investigated in a simplified model of the mitogenic kinase cascade.
    Robubi A; Mueller T; Fueller J; Hekman M; Rapp UR; Dandekar T
    Biol Chem; 2005 Nov; 386(11):1165-71. PubMed ID: 16307482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1.
    Kogut MH; Genovese KJ; He H
    Mol Immunol; 2007 Mar; 44(7):1729-36. PubMed ID: 17045653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.
    Emuss V; Garnett M; Mason C; Marais R
    Cancer Res; 2005 Nov; 65(21):9719-26. PubMed ID: 16266992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raf: a strategic target for therapeutic development against cancer.
    Beeram M; Patnaik A; Rowinsky EK
    J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear magnetic resonance and molecular dynamics studies on the interactions of the Ras-binding domain of Raf-1 with wild-type and mutant Ras proteins.
    Terada T; Ito Y; Shirouzu M; Tateno M; Hashimoto K; Kigawa T; Ebisuzaki T; Takio K; Shibata T; Yokoyama S; Smith BO; Laue ED; Cooper JA
    J Mol Biol; 1999 Feb; 286(1):219-32. PubMed ID: 9931261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
    Ikenoue T; Hikiba Y; Kanai F; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Aragaki J; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2003 Dec; 63(23):8132-7. PubMed ID: 14678966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities.
    Kanno N; Lesage G; Phinizy JL; Glaser S; Francis H; Alpini G
    Hepatology; 2002 Jun; 35(6):1329-40. PubMed ID: 12029618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
    Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L; Trail PA; Taylor I; Wilhelm SM
    Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitogenic signaling of Ras is regulated by differential interaction with Raf isozymes.
    Weber CK; Slupsky JR; Herrmann C; Schuler M; Rapp UR; Block C
    Oncogene; 2000 Jan; 19(2):169-76. PubMed ID: 10644994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf.
    Terai K; Matsuda M
    EMBO J; 2006 Aug; 25(15):3556-64. PubMed ID: 16858395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
    Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
    Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2.
    Lee M
    Biochem Biophys Res Commun; 2006 Nov; 350(2):450-6. PubMed ID: 17010316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The RAF family: an expanding network of post-translational controls and protein-protein interactions.
    Yuryev A; Wennogle LP
    Cell Res; 1998 Jun; 8(2):81-98. PubMed ID: 9669024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf heterodimerization.
    Yasuda S; Kai M; Imai S; Takeishi K; Taketomi A; Toyota M; Kanoh H; Sakane F
    J Biol Chem; 2009 Oct; 284(43):29559-70. PubMed ID: 19710016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.